￥ 人民币 $ USD € 欧元
简体中文 English 繁体中文
Menu

News

Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Exploring the potential efficacy of olaparib in cancer patients with PALB2 gene mutations

2026-02-01 22:25:32

Check Details
Discussion on factors affecting survival of patients with BRCA mutated cancer treated with Lynparza

2026-02-01 22:25:32

Check Details
Full analysis of side effects during olaparib treatment, and how to effectively respond and manage them?

2026-02-01 22:25:32

Check Details
A new dawn in the treatment of BRCA-mutated breast cancer with Lynparza

2026-02-01 22:25:32

Check Details
Overview of erdafitinib price information and current market situation in China

2026-02-01 22:25:32

Check Details
Erdafitinib is not on the market in China, and patient access methods are being discussed

2026-02-01 22:25:32

Check Details
Erdafitinib drug introduction and overview of its indications

2026-02-01 22:25:32

Check Details
Domestic purchasing guide for erdafitinib: detailed explanation of price and versions

2026-02-01 22:25:32

Check Details
Discussion on the duration of treatment with regorafenib and its determinants

2026-02-01 22:25:32

Check Details
Comparison of global market prices of regorafenib in 2024: exploring the most economical way to purchase

2026-02-01 22:25:32

Check Details
How effective is regorafenib and what side effects should we pay attention to?

2026-02-01 22:25:32

Check Details
Scope of application and performance of regorafenib in the treatment of colorectal cancer

2026-02-01 22:25:32

Check Details
Category
相关知识